“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.
Feature|Articles|October 8, 2026
How Would a TALAPRO-3 Approval Affect HRR-Altered Metastatic HSPC Care?
Author(s)Cancer Network Staff
Fact checked by: Roman Fabbricatore, Tim Cortese
Ahead of a fourth-quarter 2026 FDA decision, TALAPRO-3 investigators outline the testing, monitoring, and sequencing steps needed to adopt the regimen.
Advertisement
Advertisement
A frontline PARP inhibitor triplet for metastatic hormone-sensitive prostate cancer (HSPC) could be available for use by the end of 2026. The FDA
Related to this article
Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.
In a phase 2 trial, berzosertib/carboplatin produced a 0% overall response rate vs 15% with docetaxel/carboplatin in heavily pretreated metastatic CRPC.
At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.
Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.
At 8 years, SBRT and radical prostatectomy had similar disease control in the PACE-A trial, with less urinary incontinence after SBRT.
Advertisement
Advertisement